NZ595901A - Use of allopurinol for the treatment of hand foot skin reaction - Google Patents

Use of allopurinol for the treatment of hand foot skin reaction

Info

Publication number
NZ595901A
NZ595901A NZ595901A NZ59590110A NZ595901A NZ 595901 A NZ595901 A NZ 595901A NZ 595901 A NZ595901 A NZ 595901A NZ 59590110 A NZ59590110 A NZ 59590110A NZ 595901 A NZ595901 A NZ 595901A
Authority
NZ
New Zealand
Prior art keywords
allopurinol
treatment
skin reaction
hand foot
foot skin
Prior art date
Application number
NZ595901A
Other languages
English (en)
Inventor
Yolanda Rodemer
Original Assignee
Nobera Pharma Sl
Advancell Advanced In Vitro Cell Technologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobera Pharma Sl, Advancell Advanced In Vitro Cell Technologies S A filed Critical Nobera Pharma Sl
Publication of NZ595901A publication Critical patent/NZ595901A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595901A 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction NZ595901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (1)

Publication Number Publication Date
NZ595901A true NZ595901A (en) 2013-11-29

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595901A NZ595901A (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Country Status (22)

Country Link
US (2) US8623878B2 (enExample)
EP (2) EP2246057A1 (enExample)
JP (1) JP6007101B2 (enExample)
KR (1) KR20120049848A (enExample)
CN (1) CN102421436B (enExample)
AR (1) AR076505A1 (enExample)
AU (2) AU2010243594A1 (enExample)
BR (1) BRPI1011971A2 (enExample)
CA (1) CA2759085C (enExample)
DK (1) DK2424538T3 (enExample)
ES (1) ES2434366T3 (enExample)
HR (1) HRP20131070T1 (enExample)
IL (1) IL215831A (enExample)
ME (1) ME01567B (enExample)
MX (1) MX2011011529A (enExample)
NZ (1) NZ595901A (enExample)
PL (1) PL2424538T3 (enExample)
PT (1) PT2424538E (enExample)
RS (1) RS53005B (enExample)
RU (1) RU2543325C2 (enExample)
SI (1) SI2424538T1 (enExample)
WO (1) WO2010125143A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220713B2 (en) 2009-10-16 2015-12-29 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
TW201927292A (zh) 2017-12-13 2019-07-16 大陸商上海小午醫藥科技有限公司 一種用於預防或治療與ｅｇｆｒ被抑制相關疾病的方法
AU2019254237B2 (en) * 2018-04-16 2025-01-30 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
CA3242908A1 (en) 2022-01-05 2023-07-13 Asymmetric Therapeutics, Llc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE SKIN DISORDERS AND OTHER SKIN CONDITIONS
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3772193D1 (de) * 1987-02-13 1991-09-19 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1343492B1 (en) * 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
WO2003018102A2 (en) 2001-08-29 2003-03-06 Vectura Limited Topical administration device
CN1596111A (zh) * 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
AU2004247108A1 (en) 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法
US20050148907A1 (en) * 2003-12-24 2005-07-07 Gregory Skover Treatment of skin using a benefit agent and an apparatus
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
ES2312012T3 (es) 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
PT2035006E (pt) 2006-06-01 2010-04-22 Nobera Pharma Sl Utilização de alopurinol para o tratamento da eritrodisestesia palmo-plantar

Also Published As

Publication number Publication date
PT2424538E (pt) 2013-11-07
EP2246057A1 (en) 2010-11-03
MX2011011529A (es) 2012-02-08
HRP20131070T1 (hr) 2013-12-20
SI2424538T1 (sl) 2013-12-31
CA2759085C (en) 2016-08-16
ES2434366T3 (es) 2013-12-16
KR20120049848A (ko) 2012-05-17
IL215831A0 (en) 2012-01-31
EP2424538A1 (en) 2012-03-07
AU2016228193A1 (en) 2016-11-03
CN102421436B (zh) 2014-05-07
RU2011148355A (ru) 2013-06-10
WO2010125143A1 (en) 2010-11-04
IL215831A (en) 2016-02-29
RU2543325C2 (ru) 2015-02-27
AU2010243594A1 (en) 2011-11-10
US8623878B2 (en) 2014-01-07
AR076505A1 (es) 2011-06-15
JP2012525358A (ja) 2012-10-22
US20100280051A1 (en) 2010-11-04
BRPI1011971A2 (pt) 2016-04-26
JP6007101B2 (ja) 2016-10-12
ME01567B (me) 2014-04-20
CN102421436A (zh) 2012-04-18
EP2424538B1 (en) 2013-08-14
DK2424538T3 (da) 2013-11-04
RS53005B (sr) 2014-04-30
CA2759085A1 (en) 2010-11-04
US20140080845A1 (en) 2014-03-20
HK1168042A1 (en) 2012-12-21
PL2424538T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
NZ595901A (en) Use of allopurinol for the treatment of hand foot skin reaction
Nichols et al. Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues
IL195472A0 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
MY161078A (en) Topical formulation for a jak inhibitor
NZ603319A (en) Diabetes therapy
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
NZ702485A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
MX344329B (es) Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.
MX2011006381A (es) Uso de una composicion espumable esencialmente libre de ingredientes con actividad farmaceutica para el tratamiento de la piel humana.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
BR112014012054A2 (pt) métodos de tratamento com deferiprona
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
JP2012525358A5 (enExample)
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
WO2006102899A3 (en) Oxaprozin or closely related compound for the treatment and prevention of
NZ599227A (en) Therapeutic agent for chronic pain
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
HK1186666A (en) Combination treatment for dermatological conditions
UA92302C2 (ru) Лекарственное средство для терапии злокачественных опухолей и способ лечения злокачественных опухолей с его использованием
UA94365C2 (ru) Способ лечения спазма ныряющих венечных артерий
UA57768U (ru) Способ лечения ишемической болезни сердца c артериальной гипертензией ha фоне дислипидемии c сердечной недостаточностью у больных пожилого возраста

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20141001

LAPS Patent lapsed